FDA gets a dietary supplement registry—finally, a public database of what's in your pills
S. 3677 — Dietary Supplement Listing Act of 2026 · Filed by Richard Durbin (D-IL) · Introduced Jan 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires dietary supplement manufacturers to register their products with the FDA and submit detailed ingredient, labeling, and business information. Existing supplements have 18 months to register; new ones must register before sale. The FDA will maintain a public database of most information (keeping proprietary blend amounts and facility locations confidential) and assign each product a listing number. Manufacturers who fail to register or update listings face penalties under food-safety law.
Why we flagged it
The bill's core mechanism is a mandatory registration and listing system for dietary supplements sold in the US, with public disclosure of most product information. This is a regulatory transparency measure, not a subsidy, carve-out, or deregulation.
What the text implies
- The 18-month compliance window for existing products may create a temporary surge in FDA administrative work and potential bottlenecks in processing listings, which could delay enforcement of other FDA priorities.
- Proprietary blend amounts remain confidential, meaning consumers cannot fully verify ingredient quantities—a significant limitation on transparency that may reduce the practical value of the public database for informed comparison.
The full analysis lists 5 implications of this text.
Who stands to gain
large dietary supplement manufacturers (lower relative compliance cost, competitive advantage); FDA (expanded regulatory capacity and data infrastructure); software/IT vendors (database development and compliance-tracking tools)